Search Results - everett+stone

9 Results Sort By:
Modified kynureninase enzymes for cancer therapy
This invention describes modified kynureninase enzymes, particularly human enzymes, for degrading kynurenine. These enzymes can be used in compositions and methods for treating cancer by depleting kynurenine levels. Background Cancer immunotherapy has emerged as a promising approach to treating a wide range of malignancies. The goal of immunotherapy...
Published: 11/5/2024   |   Inventor(s): George Georgiou, Everett Stone, John Blazeck, Nicholas Marshall, Wei-Cheng Lu
Keywords(s):  
Category(s): Life sciences > Research tools > Tool/assay/screening platform, Life sciences > Therapeutics > Gene therapy
Biotechnological platform for engineering enzymes to degrade L‑Cyst(e)ine for cancer therapy
The invention involves engineering a modified enzyme, cystathionine-gamma-lyase, to degrade L-cyst(e)ine, targeting cancer cells reliant on this amino acid. The enzyme exhibits improved stability and reduced immunogenicity, making it suitable for therapeutic applications in cancer treatment. Background Cancer cells often exhibit altered metabolic...
Published: 11/5/2024   |   Inventor(s): George Georgiou, Everett Stone
Keywords(s):  
Category(s): Life sciences > Therapeutics > Gene therapy, Life sciences > Research tools > Tool/assay/screening platform
Biotechnological approach for cancer treatment through kynurenine depletion using engineered enzymes​​​​​
This invention describes engineered kynureninase enzymes that degrade kynurenine, a metabolite linked to cancer progression. These enzymes, optimized for human therapy, can be modified with polyethylene glycol to enhance stability and circulation, offering potential in cancer treatment when combined with other therapies like immunotherapy. Background Cancer...
Published: 11/5/2024   |   Inventor(s): George Georgiou, Everett Stone
Keywords(s):  
Category(s): Life sciences > Metabolic engineering, Life sciences > Therapeutics > Gene therapy
Enhanced cancer treatment through methionine depletion
The invention involves engineering a modified human cystathionine-γ-lyase enzyme to degrade methionine, an amino acid essential for cancer cell growth. This modified enzyme, with specific amino acid substitutions, offers enhanced catalytic activity, stability, and reduced immunogenicity, making it suitable for cancer treatment by depleting methionine...
Published: 9/13/2024   |   Inventor(s): George Georgiou, Everett Stone, Wei-Cheng Lu
Keywords(s):  
Category(s): Life sciences > Metabolic engineering, Life sciences > Therapeutics > Gene therapy
Engineered enzymes for enhanced kynurenine degradation in cancer therapy​​
The technology describes a modified human kynureninase enzyme with enhanced catalytic efficiency for degrading kynurenine, achieved through specific amino acid substitutions. This enzyme, used in therapeutic applications, reduces kynurenine levels to mitigate tumor-mediated immune suppression and promote anti-tumor immune responses. Background Cancer...
Published: 5/20/2025   |   Inventor(s): George Georgiou, Everett Stone, John Blazeck
Keywords(s):  
Category(s): Life sciences > Therapeutics > Gene therapy, Life sciences > Research tools > Tool/assay/screening platform
Therapeutic applications of engineered L-Cyst(e)ine-degrading enzymes
The technology describes engineered primate cystathionine-γ-lyase enzymes with specific amino acid modifications that enhance their ability to degrade L-cyst(e)ine. These enzymes, intended for therapeutic use in cancer and cystinuria, improve stability and reduce immunogenicity. Background Cancer and cystinuria present significant therapeutic...
Published: 11/5/2024   |   Inventor(s): George Georgiou, Shira Cramer, Everett Stone
Keywords(s):  
Category(s): Life sciences > Research tools > Tool/assay/screening platform, Life sciences > Therapeutics > Gene therapy
Pharmacologically optimized human kynureninase variants for cancer treatment
­The invention describes a modified kynureninase enzyme with enhanced catalytic efficiency and stability for therapeutic applications, particularly in cancer treatment. It depletes kynurenine, aiding cancer therapy alone or with other treatments, and can be PEGylated for increased in vivo half-life. Background Cancer cells often manipulate metabolic...
Published: 11/5/2024   |   Inventor(s): George Georgiou, Everett Stone, John Blazeck, Christos Karamitros
Keywords(s):  
Category(s): Life sciences > Therapeutics > Gene therapy, Life sciences > Research tools > Tool/assay/screening platform
Engineered enzymes for cystinuria treatment
The invention describes engineered primate cystathionine-gamma-lyase (CGL) enzymes with specific amino acid modifications to efficiently degrade L‑cystine and L-cysteine. These enzymes are designed to treat cystinuria by reducing cystine levels in the body, preventing cystine stone formation. Background Cystinuria is a genetic disorder caused by mutations...
Published: 11/5/2024   |   Inventor(s): Everett Stone, Wei-Cheng Lu, Christos Karamitros
Keywords(s):  
Category(s): Life sciences > Therapeutics > Gene therapy
Human enzyme-mediated depletion of serine in cancer
Engineered human serine dehydratase enzymes are designed to efficiently degrade serine, an amino acid crucial to cancer cell metabolism, and inhibit cancer growth. These enzymes, with improved stability, activity, and bio­availability, offer a targeted cancer treatment option with fewer adverse effects. Background Traditional chemotherapeutic...
Published: 8/29/2024   |   Inventor(s): Everett Stone, Ebru Cayir, Daniel Diaz, Raghav Shroff
Keywords(s):  
Category(s): Life sciences > Therapeutics > Small molecule, Life sciences > Research tools